Leflunomide Sandoz

Leflunomide, the active ingredient in Leflunomide Sandoz, is a disease-modifying antirheumatic drug (DMARD) presented as a tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce inflammation and slow joint damage.

GNH USA supplies Leflunomide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease-modifying antirheumatic drug that acts on autoimmune joint disease pathways.

Rheumatoid arthritis: reduces disease activity, pain, and structural joint damage. Psoriatic arthritis: improves skin lesions and joint inflammation. Moderate to severe rheumatoid arthritis in adults: provides disease control when conventional therapy is insufficient.

Leflunomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhoea or nausea. - Elevated liver enzymes. - Hypertension. - Alopecia or mild rash.

Serious or Rare Side Effects: - Severe liver injury or hepatitis. - Bone‑marrow suppression leading to neutropenia or anemia. - Pulmonary toxicity, including interstitial lung disease. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Leflunomide, several safety considerations should be observed.

Pregnancy: contraindicated; teratogenic risk requires effective contraception. Liver function: monitor transaminases before and during therapy. Hematology: regular complete blood counts to detect bone‑marrow suppression. Infection: avoid initiating therapy in patients with active severe infections. Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Leflunomide interacts with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: may increase anticoagulant effect and bleeding risk. - Methotrexate: combined use can heighten hepatotoxicity and bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Cholestyramine or activated charcoal: can reduce leflunomide plasma levels. - CYP1A2 inducers (e.g., rifampicin): may lower drug exposure. - Live vaccines: increased risk of infection; avoid during therapy.